Comparative treatment effectiveness of oral fingolimod and injectable disease modifying agents in multiple sclerosis

被引：0
|
作者：
Earla, Jagadeswara Rao [1 ]
Hutton, George Joseph [2 ]
Thornton, J. Douglas [1 ]
Chen, Hua [1 ]
Johnson, Michael L. [1 ]
Aparasu, Rajender R. [1 ]
机构：
[1] Univ Houston, Coll Pharm, Houston, TX 77030 USA
[2] Baylor Coll Med, Houston, TX 77030 USA
来源：
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY | 2020年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
3956
引用
收藏
页码：118 / 118
页数：1
相关论文
共 50 条
  • [41] An evaluation of adherence in patients with multiple sclerosis newly initiating treatment with a self-injectable or an oral disease-modifying drug
    Munsell, Michael
    Frean, Molly
    Menzin, Joseph
    Phillips, Amy L.
    PATIENT PREFERENCE AND ADHERENCE, 2017, 11 : 55 - 62
  • [42] Real-world effectiveness of oral disease-modifying therapies for multiple sclerosis
    Thanh Phuong Pham Nguyen
    Thibault, Dylan
    Willis, Allison
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2020, 29 : 124 - 125
  • [43] Hepatitis C during disease modifying therapy with Fingolimod for Relapsing Remitting Multiple Sclerosis: diagnosis and treatment
    Aslanyan, Aram
    Anwar-Hashim, Zoheb
    Siripurapu, Rekha
    Mihalova, Tatiana
    BMJ CASE REPORTS, 2021, 14 (02)
  • [44] Oral fingolimod for the treatment of patients with relapsing forms of multiple sclerosis
    Singer, B.
    Ross, A. P.
    Tobias, K.
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2011, 65 (08) : 887 - 895
  • [45] Multiple Sclerosis: Overview of Disease-Modifying Agents
    Finkelsztejn, Alessandro
    PERSPECTIVES IN MEDICINAL CHEMISTRY, 2014, 6 : 65 - 72
  • [46] ORAL FINGOLIMOD FOR THE TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS
    Vosiliou, S.
    DRUGS OF TODAY, 2010, 46 (05) : 315 - 325
  • [47] Perspectives and experiences of Dutch multiple sclerosis patients and multiple sclerosis-specialized neurologists on injectable disease-modifying treatment
    Visser, Leo H.
    Heerings, Marco A.
    Jongen, Peter J.
    van der Hiele, Karin
    PATIENT PREFERENCE AND ADHERENCE, 2016, 10 : 659 - 667
  • [48] Comparative Effectiveness and Cost-Effectiveness of Natalizumab and Fingolimod in Patients with Inadequate Response to Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis in the United Kingdom
    Spelman, Timothy
    Herring, William L.
    Zhang, Yuanhui
    Tempest, Michael
    Pearson, Isobel
    Freudensprung, Ulrich
    Acosta, Carlos
    Dort, Thibaut
    Hyde, Robert
    Havrdova, Eva
    Horakova, Dana
    Trojano, Maria
    De Luca, Giovanna
    Lugaresi, Alessandra
    Izquierdo, Guillermo
    Grammond, Pierre
    Duquette, Pierre
    Alroughani, Raed
    Pucci, Eugenio
    Granella, Franco
    Lechner-Scott, Jeannette
    Sola, Patrizia
    Ferraro, Diana
    Grand'Maison, Francois
    Terzi, Murat
    Rozsa, Csilla
    Boz, Cavit
    Hupperts, Raymond
    Van Pesch, Vincent
    Oreja-Guevara, Celia
    van der Walt, Anneke
    Jokubaitis, Vilija G.
    Kalincik, Tomas
    Butzkueven, Helmut
    PHARMACOECONOMICS, 2022, 40 (03) : 323 - 339
  • [49] Comparative Effectiveness and Cost-Effectiveness of Natalizumab and Fingolimod in Patients with Inadequate Response to Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis in the United Kingdom
    Timothy Spelman
    William L. Herring
    Yuanhui Zhang
    Michael Tempest
    Isobel Pearson
    Ulrich Freudensprung
    Carlos Acosta
    Thibaut Dort
    Robert Hyde
    Eva Havrdova
    Dana Horakova
    Maria Trojano
    Giovanna De Luca
    Alessandra Lugaresi
    Guillermo Izquierdo
    Pierre Grammond
    Pierre Duquette
    Raed Alroughani
    Eugenio Pucci
    Franco Granella
    Jeannette Lechner-Scott
    Patrizia Sola
    Diana Ferraro
    Francois Grand’Maison
    Murat Terzi
    Csilla Rozsa
    Cavit Boz
    Raymond Hupperts
    Vincent Van Pesch
    Celia Oreja-Guevara
    Anneke van der Walt
    Vilija G. Jokubaitis
    Tomas Kalincik
    Helmut Butzkueven
    PharmacoEconomics, 2022, 40 : 323 - 339
  • [50] Fostering adherence to injectable disease-modifying therapies in multiple sclerosis
    Lugaresi, Alessandra
    Rottoli, Maria Rosa
    Patti, Francesco
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2014, 14 (09) : 1029 - 1042
12345